Chemotherapy before and after surgery to remove liver mets reduces the risk of colorectal cancer recurrence.

Posted by Kate Murphy on June 25th, 2007

 

NEWS FROM ASCO 2007

Chemotherapy given before and after surgery to remove colorectal cancer tumors that have spread to the liver significantly improves three-year progression-free survival.

Results of a randomized phase III clinical trial were discussed at the 2007 ASCO annual meeting in Chicago.  Patients who had cancer that had spread to their liver  considered surgically removable by their doctors either had surgery to remove the liver tumors right away or were assigned to a chemotherapy group.

Patients in the trial had four or fewer liver metastases and had no other cancer outside their livers. 

The chemotherapy group received 6 FOLFOX4 treatments before surgery and 6 treatments afterwards.

After three years there was almost a ten percent absolute improvement in progression-free survival in the group that had chemotherapy — 42.4 percent had not had their cancer return or spread outside the liver versus 33.2 percent for those who had surgery alone.

Bernard Nordlinger M.D. presented the results of the international EPOC trial at the ASCO Plenary session on Monday, June 4th.  In discussing the improved progression-free survival with the use of chemotherapy, he concluded:

This treatment should be proposed as a new standard for these patients and should be delivered by a multidisciplinary team.

Nicholas Petrelli, M.D., a surgical oncologist, disagreed that the approach should be the standard first choice for treating resectable liver metastases.  In a discussion following Nordlinger’s presentation, Petrelli pointed out that chemotherapy can harm normal liver tissue and lead to surgical complications.

He said that doing surgery first is still a good option for people whose liver metastases are resectable.

He called for a clinical trial to compare effectiveness of both pre and post surgical chemotherapy to improve survival.

SOURCE: Nordlinger et. al. Abstract #LBA5 ASCO 2007.

Comments (0): Add a comment

Leave a Reply

Your comments are welcome. However, specific medical advice will not be provided. Generic QUESTIONS can be directed to our Answer Line team at http://fightcolorectalcancer.org/awareness/answer-line or by calling us at 1-877-427-2111 9:00 AM – 5:00 PM Eastern time, Monday – Friday. We urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. Fight Colorectal Cancer is not responsible for the medical accuracy of any comments left by persons other than Fight Colorectal Cancer staff members. Fight Colorectal Cancer staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites.